DDInter222 DDInter416
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s . Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity . It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers . The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot .
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfinpyrazone
Sulfinpyrazone {u} (Compound) resembles {v} (Compound) Clotrimazole
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Clotrimazole
Bortezomib {u} (Compound) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Clotrimazole
Bortezomib {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Clotrimazole
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfinpyrazone
Sulfinpyrazone {u} (Compound) resembles {v} (Compound) Diphenoxylate
Diphenoxylate {u} (Compound) resembles {v} (Compound) Clotrimazole
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Methadone
Methadone {u} (Compound) resembles {v} (Compound) Clotrimazole
Bortezomib {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Loperamide
Loperamide {u} (Compound) resembles {v} (Compound) Clotrimazole
Bortezomib {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Loperamide
Loperamide {u} (Compound) resembles {v} (Compound) Clotrimazole
Bortezomib {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Methadone
Methadone {u} (Compound) resembles {v} (Compound) Clotrimazole
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phenylbutazone
Phenylbutazone {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) resembles {v} (Compound) Clotrimazole
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) resembles Clotrimazole (Compound)
Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Clotrimazole (Compound)
Bortezomib (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Clotrimazole (Compound)
Bortezomib (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Clotrimazole (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) resembles Diphenoxylate (Compound) and Diphenoxylate (Compound) resembles Clotrimazole (Compound)
Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Methadone (Compound) and Methadone (Compound) resembles Clotrimazole (Compound)
Bortezomib (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Loperamide (Compound) and Loperamide (Compound) resembles Clotrimazole (Compound)
Bortezomib (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Loperamide (Compound) and Loperamide (Compound) resembles Clotrimazole (Compound)
Bortezomib (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Methadone (Compound) and Methadone (Compound) resembles Clotrimazole (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Clotrimazole (Compound)